Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied. Streptomycin is excreted rapidly in the urine by glomerular filtration and a pharmacokinetic interaction with emtricitabine is unlikely. Since tenofovir is primarily eliminated by the kidneys, coadministration with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of tenofovir or the coadministered drug. Tenofovir-DF should be avoided with concurrent or recent use of a nephrotoxic agent. If concomitant use of tenofovir-DF and nephrotoxic agents is unavoidable, renal function should be closely monitored.
Use of emtricitabine/tenofovir-DF should be avoided with concurrent or recent use of a nephrotoxic medicinal product like aminoglycosides.
Truvada Summary of Product Characteristics Gilead Sciences Ltd, June 2018.
Coadministration of Truvada with drugs that are eliminated by active tubular secretion may increase concentrations of FTC, tenofovir, and/or the coadministered drug. Some examples include, but are not limited to, aminoglycosides.
Truvada US Prescribing Information, Gilead Sciences Inc, May 2018.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking